The PhotoMedex (PHMD) Getting Somewhat Critical Press Coverage, Analysis Shows

The PhotoMedex (PHMD) Getting Somewhat Critical Press Coverage, Analysis Shows

Separately, ValuEngine upgraded shares of PhotoMedex from a “strong sell” rating to a “sell” rating in a research note on Friday.

News coverage about PhotoMedex (NASDAQ:PHMD) has been trending somewhat negative recently, Alpha One Sentiment Analysis reports. Alpha One, a service of Accern, identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PhotoMedex earned a news impact score of -0.10 on Alpha One’s scale. Alpha One also assigned headlines about the medical equipment provider an impact score of 93 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the next several days.

About PhotoMedex PhotoMedex, Inc is a global health products and services company providing integrated disease management and solutions to dermatologists, professional aestheticians and consumers. The Company provides products and services that address skin diseases and conditions, including acne and photo damage. The Company operates through three business segments: Consumer segment, Physician Recurring segment and Professional segment.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:PHMD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for PhotoMedex Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PhotoMedex Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment